Last reviewed · How we verify
Ides (IMLIFIDASE)
At a glance
| Generic name | IMLIFIDASE |
|---|---|
| Sponsor | Hansa Biopharma AB |
| Target | Immunoglobulin gamma (IgG), heavy chain |
| Modality | Enzyme |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 2020 |
Approved indications
- Renal transplant rejection
- Transplant of kidney
Common side effects
Key clinical trials
- A Study With Imlifidase in Anti-GBM Disease (PHASE3)
- Imlifidase for Highly Sensitized Kidney Transplant Recipients With a posItive crossmAtch Against a Deceased Donor: Results of Kidney Transplantations Performed in Accordance to the French Guidelines.
- A Long-term Follow-up Trial of Patients Previously Treated With Imlifidase Prior to Kidney Transplantation and a Non-comparative Transplanted Patient Group (PHASE3)
- A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Imlifidase Infusion in Participants With Duchenne Muscular Dystrophy (DMD) Determined to Have Pre-existing Antibodies to Recombinant Adeno-Associated Virus Serotype (rAAVrh74) (PHASE1)
- Survival and Dialysis Independency in Highly Sensitized Patients After Desensitization With Imlifidase and Tx of Kidneys
- A Study to Investigate DSA Rebound in Patients Treated With Imlifidase Prior to Transplantation (PHASE2)
- Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney Tx (PHASE3)
- An Long-term Follow-up Trial of Kidney Tx Patients Treated With Imlifidase or PE After an AMR
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ides CI brief — competitive landscape report
- Ides updates RSS · CI watch RSS
- Hansa Biopharma AB portfolio CI